/PVLA

PVLA Stock - Palvella Therapeutics, Inc.

Q: What is the analyst price target for PVLA?

Analyst price target information is not currently available for PVLA.

Q: What is PVLA's market cap?

Market capitalization information is not currently available for PVLA.

Healthcare|Biotechnology|NASDAQ

$103.54+3.04%

+$3.05 (+3.04%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

High Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

100

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+76.9%upside

Target: $183.16

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for PVLA

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-0.15

52W High$114.69

52W Low$12.10

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021
Revenue	N/A	N/A	$25.90M	$31.42M
Gross Profit	N/A	N/A	$23.12M	$29.05M
Gross Margin	N/A	N/A	89.3%	92.5%
Operating Income	$-14,095,000	$-11,869,000	$-43,474,000	$-51,831,000
Net Income	$-17,434,000	$18.69M	$-33,277,000	$-45,738,000
Net Margin	N/A	N/A	-128.5%	-145.6%
EPS	$-7.83	$14.74	$-29.61	$-56.69

Company Overview

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.

Visit Website

Earnings History & Surprises

PVLA

Beat Rate

64%

Last 11 quarters

Avg Surprise

+108.9%

EPS vs Estimate

Beats / Misses

7/4

Last 12 quarters

Latest EPS

$-1.03

Q4 2025

EPS Surprise History

Q1 24

+61.4%

$-3.71vs$-9.60

Q2 24

+58.3%

$-2.00vs$-4.80

Q3 24

-15.0%

$-2.76vs$-2.40

Q4 24

-301.8%

$-2.19vs$-0.55

Q1 25

+1125.6%

$4.00vs$-0.39

Q2 25

+78.2%

$-0.74vs$-3.40

Q3 25

-10.3%

$-0.86vs$-0.78

Q4 25

-21.2%

$-1.03vs$-0.85

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 30, 2026	$-0.96	—	—	—
Q4 2025	Nov 11, 2025	$-0.85	$-1.03	-21.2%	✗ MISS
Q3 2025	Aug 14, 2025	$-0.78	$-0.86	-10.3%	✗ MISS
Q2 2025	May 15, 2025	$-3.40	$-0.74	+78.2%	✓ BEAT
Q1 2025	Mar 31, 2025	$-0.39	$4.00	+1125.6%	✓ BEAT
Q4 2024	Nov 13, 2024	$-0.55	$-2.19	-301.8%	✗ MISS
Q3 2024	Aug 14, 2024	$-2.40	$-2.76	-15.0%	✗ MISS
Q2 2024	May 16, 2024	$-4.80	$-2.00	+58.3%	✓ BEAT
Q1 2024	Mar 30, 2024	$-9.60	$-3.71	+61.4%	✓ BEAT
Q4 2023	Nov 15, 2023	$-8.80	$-8.70	+1.1%	✓ BEAT
Q3 2023	Aug 11, 2023	$-12.54	$3.62	+128.9%	✓ BEAT
Q2 2023	May 11, 2023	$-14.68	$-1.17	+92.0%	✓ BEAT

Frequently Asked Questions about PVLA

What is PVLA's current stock price?

Palvella Therapeutics, Inc. (PVLA) is currently trading at $103.54 per share. The stock has moved +3.04% today.

What is the analyst price target for PVLA?

The average analyst price target for PVLA is $183.19, based on 1 analyst.

What sector is Palvella Therapeutics, Inc. in?

Palvella Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is PVLA's market cap?

Palvella Therapeutics, Inc. has a market capitalization of $1.23 billion, making it a small-cap company.

Does PVLA pay dividends?

No, Palvella Therapeutics, Inc. does not currently pay a dividend to shareholders.